European Union — European Medicines Agency & International — European Commission

European Union — European Medicines Agency: The European Union — European Medicines Agency's CHMP recommended the revocation of the marketing authorization for TAVNEOS, impacting its availability in the EU.

International — European Commission: The International — European Commission is expected to make a final decision on the CHMP's recommendation, which will determine the future of TAVNEOS in the EU.

European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is the overarching regulatory body whose CHMP adopted the positive opinion for DAYBU, facilitating its potential market entry in the EU.

International — European Commission: The International — European Commission will review the CHMP's positive opinion and is expected to issue a final decision on the marketing authorization for DAYBU, which would apply to all EU member states.

European Union — European Medicines Agency: The European Union — European Medicines Agency's Committee for Orphan Medicinal Products provided a positive opinion for Etavopivat, leading to its Orphan Drug designation by the International — European Commission.

International — European Commission: The International — European Commission granted Etavopivat Orphan Drug designation, based on a positive opinion from the Committee for Orphan Medicinal Products of the European Union — European Medicines Agency, which will facilitate its development and potential approval in Europe.